Stock listing
LS Exchange:A3DWYX Cocrystal Pharma, Inc. Aktie
German listing (LS Exchange) of Cocrystal Pharma, Inc. · home listing NASDAQ:COCP
Follow Cocrystal Pharma, Inc. into a list and get an email when it puts out news.
Home listing price · NASDAQ:COCP
$0.95 USD -0.03 (-2.8%)
Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:COCP
- Day range
- $0.91 – $0.968 USDNov 20, 2026
- Volume
- 42,947 sharesNov 20, 2026
- Market cap
- $18.30M USDAt the close on Nov 20, 2026 · price × 19.26M shares outstanding
- 52-week range
- $0.76 – $2.03 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $48,483 USDMedian day 33,049 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:COCP · Home | $0.95 USD | -0.027 (-2.8%) | 42,947 | $0.95 | $0.968 | $0.91 | $0.977 | Close on Nov 20, 2026 |
| Frankfurt:8CC | €0.85 EUR | -0.02 (-2.3%) | — | €0.85 | €0.85 | €0.85 | €0.87 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:COCP · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $0.95 | -0.027 | -2.8% | $0.95 | $0.968 | $0.91 | 42,947 | |
| $0.977 | -0.033 | -3.3% | $0.98 | $0.99 | $0.96 | 7,483 | |
| $1.01 | +0.032 | +3.3% | $1.00 | $1.03 | $0.958 | 40,554 | |
| $0.978 | -0.002 | -0.2% | $1.00 | $1.01 | $0.96 | 30,636 | |
| $0.98 | -0.01 | -1.0% | $1.02 | $1.03 | $0.98 | 12,132 | |
| $0.99 | -0.03 | -2.9% | $0.989 | $1.04 | $0.989 | 22,080 | |
| $1.02 | -0.01 | -1.0% | $1.025 | $1.05 | $1.00 | 23,638 | |
| $1.03 | -0.075 | -6.8% | $1.06 | $1.11 | $1.03 | 33,049 | |
| $1.105 | +0.065 | +6.2% | $1.04 | $1.14 | $0.99 | 62,169 | |
| $1.04 | +0.04 | +4.0% | $0.98 | $1.04 | $0.98 | 26,563 | |
| $1.00 | -0.01 | -1.0% | $1.04 | $1.04 | $0.988 | 50,514 | |
| $1.01 | -0.06 | -5.6% | $1.07 | $1.088 | $1.01 | 22,812 | |
| $1.07 | +0.01 | +0.9% | $1.03 | $1.093 | $1.03 | 27,859 | |
| $1.06 | +0.065 | +6.5% | $1.03 | $1.07 | $1.03 | 13,818 | |
| $0.995 | +0.015 | +1.5% | $0.95 | $1.008 | $0.95 | 62,764 | |
| $0.98 | -0.01 | -1.0% | $0.97 | $0.98 | $0.97 | 14,735 | |
| $0.99 | +0.009 | +0.9% | $0.981 | $1.00 | $0.97 | 32,735 | |
| $0.981 | +0.009 | +0.9% | $0.94 | $1.00 | $0.94 | 15,380 | |
| $0.972 | +0.022 | +2.3% | $0.97 | $1.01 | $0.962 | 21,940 | |
| $0.95 | +0.04 | +4.4% | $0.92 | $1.07 | $0.92 | 43,500 | |
| $0.91 | -0.03 | -3.2% | $0.94 | $1.00 | $0.91 | 17,100 | |
| $0.94 | 0.00 | 0.0% | $0.97 | $0.97 | $0.93 | 7,500 | |
| $0.94 | -0.01 | -1.1% | $0.91 | $0.98 | $0.91 | 15,300 | |
| $0.95 | -0.07 | -6.9% | $1.01 | $1.02 | $0.91 | 152,300 | |
| $1.02 | -0.01 | -1.0% | $1.04 | $1.06 | $1.01 | 22,800 | |
| $1.03 | -0.01 | -1.0% | $1.02 | $1.06 | $1.01 | 45,500 | |
| $1.04 | -0.04 | -3.7% | $1.05 | $1.08 | $1.04 | 46,000 | |
| $1.08 | +0.02 | +1.9% | $1.05 | $1.11 | $1.02 | 86,700 | |
| $1.06 | -0.01 | -0.9% | $1.07 | $1.08 | $1.05 | 9,000 | |
| $1.07 | 0.00 | 0.0% | $1.06 | $1.08 | $1.06 | 4,000 | |
| $1.07 | +0.01 | +0.9% | $1.06 | $1.10 | $1.06 | 29,000 | |
| $1.06 | -0.05 | -4.5% | $1.11 | $1.11 | $1.06 | 30,200 | |
| $1.11 | 0.00 | 0.0% | $1.11 | $1.13 | $1.10 | 28,500 | |
| $1.11 | -0.04 | -3.5% | $1.18 | $1.18 | $1.11 | 41,200 | |
| $1.15 | +0.01 | +0.9% | $1.17 | $1.17 | $1.14 | 13,700 | |
| $1.14 | -0.01 | -0.9% | $1.18 | $1.18 | $1.12 | 68,000 | |
| $1.15 | +0.03 | +2.7% | $1.14 | $1.19 | $1.12 | 12,700 | |
| $1.12 | -0.09 | -7.4% | $1.24 | $1.24 | $1.10 | 121,000 | |
| $1.21 | +0.04 | +3.4% | $1.19 | $1.22 | $1.15 | 32,100 | |
| $1.17 | +0.02 | +1.7% | $1.18 | $1.18 | $1.14 | 13,400 | |
| $1.15 | -0.04 | -3.4% | $1.21 | $1.21 | $1.13 | 47,900 | |
| $1.19 | 0.00 | 0.0% | $1.17 | $1.28 | $1.16 | 26,100 | |
| $1.19 | 0.00 | 0.0% | $1.21 | $1.28 | $1.19 | 69,000 | |
| $1.19 | -0.02 | -1.7% | $1.20 | $1.25 | $1.19 | 41,100 | |
| $1.21 | +0.07 | +6.1% | $1.14 | $1.25 | $1.14 | 176,500 | |
| $1.14 | 0.00 | 0.0% | $1.14 | $1.15 | $1.12 | 13,800 | |
| $1.14 | 0.00 | 0.0% | $1.13 | $1.17 | $1.11 | 46,800 | |
| $1.14 | -0.03 | -2.6% | $1.21 | $1.23 | $1.12 | 34,000 | |
| $1.17 | -0.07 | -5.6% | $1.27 | $1.27 | $1.17 | 23,100 | |
| $1.24 | +0.01 | +0.8% | $1.26 | $1.29 | $1.22 | 58,500 | |
| $1.23 | -0.01 | -0.8% | $1.26 | $1.28 | $1.22 | 53,600 | |
| $1.24 | +0.06 | +5.1% | $1.18 | $1.29 | $1.18 | 111,300 | |
| $1.18 | +0.05 | +4.4% | $1.15 | $1.20 | $1.12 | 61,400 | |
| $1.13 | 0.00 | 0.0% | $1.12 | $1.14 | $1.10 | 42,900 | |
| $1.13 | -0.03 | -2.6% | $1.16 | $1.16 | $1.12 | 29,200 | |
| $1.16 | +0.04 | +3.6% | $1.15 | $1.17 | $1.11 | 55,200 | |
| $1.12 | -0.04 | -3.4% | $1.17 | $1.17 | $1.10 | 34,800 | |
| $1.16 | +0.06 | +5.5% | $1.10 | $1.16 | $1.10 | 48,300 | |
| $1.10 | -0.04 | -3.5% | $1.18 | $1.18 | $1.10 | 28,700 | |
| $1.14 | +0.02 | +1.8% | $1.10 | $1.17 | $1.10 | 44,900 | |
| $1.12 | -0.01 | -0.9% | $1.13 | $1.17 | $1.12 | 18,800 | |
| $1.13 | +0.02 | +1.8% | $1.11 | $1.18 | $1.10 | 71,800 | |
| $1.11 | -0.04 | -3.5% | $1.19 | $1.19 | $1.10 | 46,000 | |
| $1.15 | -0.02 | -1.7% | $1.19 | $1.21 | $1.10 | 84,200 | |
| $1.17 | +0.02 | +1.7% | $1.16 | $1.23 | $1.13 | 175,900 |
Splits
2 splits since 2018 · NASDAQ:COCP · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-12 | Consolidation | |
| 1-for-30 | Consolidation |
- Ticker
- LS Exchange:A3DWYX
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- LS Exchange
- Currency
- EUR
What changed lately
Latest news release · Nov 15, 2026
Cocrystal Pharma Provides Business Update and Reports Third Quarter 2026 Financial Results
Latest deck · Apr 30, 2026
2026 International Society For Antiviral Research (ICAR 2026)
Conference · 17 slides
Latest news
Cocrystal Pharma Provides Business Update and Reports Third Quarter 2026 Financial Results
Nov 15, 2026
Closed $0.978 (-0.2%) on Nov 16, 2026
Cocrystal Pharma Announces Last Subject Dosed in Phase 1b Human Challenge Study Evaluating CDI-988 for Norovirus Prevention and Treatment
Sep 9, 2026
Closed $1.24 (+5.1%) on Sep 9, 2026
Cocrystal Pharma Appoints Carol Brosgart, MD to its Board of Directors
Aug 17, 2026
Closed $1.09 (-2.7%) on Aug 17, 2026
Cocrystal Pharma Announces $5 Million Private Placement with OPKO Health
Aug 3, 2026
Closed $0.94 (+14.6%) on Aug 3, 2026
Cocrystal Pharma Appoints James Sapirstein, Biopharma Industry Leader with Extensive Antiviral Development Experience, as Chief Executive Officer
Jun 3, 2026
Closed $1.06 (+1.0%) on Jun 3, 2026
Cocrystal Pharma Announces Discovery of Pan-Viral Inhibitors Targeting Hantavirus, Bunyavirus and Influenza
May 26, 2026
Closed $1.13 (-1.7%) on May 26, 2026
Cocrystal Pharma Provides Business Update and Reports First Quarter 2026 Financial Results
May 15, 2026
Closed $1.20 (-4.8%) on May 15, 2026
COCP: Fast Track Designation for CDI-988 for Norovirus Infection Treatment and Prevention
Apr 7, 2026
Closed $1.47 (-2.0%) on Apr 7, 2026
Cocrystal Pharma Receives FDA Fast Track Designation for CDI-988 for Norovirus Infection Treatment and Preventive
Apr 2, 2026
Closed $1.51 (+48.0%) on Apr 2, 2026
Cocrystal Pharma Reports 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs
Mar 31, 2026
Closed $1.01 (+1.0%) on Mar 31, 2026
Cocrystal Pharma, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 15 in the last 12 months · 153 in all · newest Nov 15, 2026 · oldest 2019
- Decks
- 29 decks · latest Apr 30, 2026
Where Cocrystal Pharma, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:COCP · Home listing | NASDAQ | United States | USD |
| Tradegate:8CC | Tradegate | Germany | EUR |
| Lang & Schwarz:A3DWYX | Lang & Schwarz | Germany | EUR |
| LS Exchange:A3DWYX · This page | LS Exchange | Germany | EUR |
| gettex:8CC | gettex | Germany | EUR |
| BOATS:COCP | BOATS | United States | USD |
| Dusseldorf:8CC | Dusseldorf | Germany | EUR |
| Frankfurt:8CC | Frankfurt | Germany | EUR |
| Munich:8CC | Munich | Germany | EUR |
| Stuttgart:8CC | Stuttgart | Germany | EUR |
Valuation
EV/sales 33.8× against a median of 4.9×: the highest of 4 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $14.69M USD
- P/E
- Loss
- EV/sales
- 33.8×
- EV/EBITDA
- Negative EBITDA
- Price/book
- 6.8×
- Gross margin
- Revenue too small
- Operating margin
- Revenue too small
- Net margin
- Revenue too small
- Debt to equity
- 0.5×
- Beta vs S&P 500
- 1.21
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Cocrystal Pharma, Inc. · NASDAQ:COCP | US$18.30M | US$14.69M | n/a | 33.8× | n/a | 6.8× | n/a | 0.5× | 1.21 |
| TransCode Therapeutics, Inc. · NASDAQ:RNAZ | US$20.07M | US$15.44M | n/a | n/a | n/a | 0.6× | n/a | 0.0× | 1.03 |
| Adicet Bio, Inc. · NASDAQ:ACET | US$20.03M | US$5.02M | n/a | n/a | n/a | 0.2× | n/a | 0.1× | 2.02 |
| IGC Pharma, Inc. · AMEX:IGC | US$19.60M | US$19.19M | n/a | n/a | n/a | 3.0× | n/a | 0.0× | 1.09 |
| Provectus Biopharmaceuticals, Inc. · OTC:PVCT | US$19.12M | US$18.94M | n/a | n/a | n/a | n/a | n/a | n/a | -0.21 |
| LeonaBio, Inc. · NASDAQ:LONA | US$19.03M | −US$12.82M | n/a | n/a | n/a | 1.2× | n/a | 0.0× | 1.04 |
| Syntara Limited · ASX:SNT | US$18.20M | US$9.23M | n/a | 2.0× | n/a | 1.7× | −129.8% | 0.0× | n/a |
| Marker Therapeutics, Inc. · NASDAQ:MRKR | US$18.17M | US$9.13M | n/a | 4.9× | n/a | 1.7× | −461.1% | 0.0× | 1.49 |
| Resverlogix Corp. · TSX:RVX | US$18.01M | US$95.55M | n/a | n/a | n/a | n/a | n/a | n/a | 0.26 |
| SynCore Biotechnology Co., Ltd. · TPEX:4192 | US$16.80M | US$12.38M | n/a | 15.6× | n/a | 2.5× | −178.5% | 0.0× | n/a |
| Initiator Pharma A/S · OMXSTO:INIT | US$16.76M | US$15.67M | n/a | n/a | n/a | 13.4× | n/a | 1.1× | n/a |
| Median of the others | US$18.62M | US$13.91M | 4.9× | 1.7× | −178.5% | 0.0× | 1.04 |
Forecasts
2 strong buy · Analysts' consensus from EODHD, read Nov 18, 2026. Not 6ix's view and not investment advice.
- Price target
- 8.00 USD · Analysts' mean
- EPS, year to Dec 2026
- -0.72 · 2 analysts
- Revenue, year to Dec 2026
- 110M · 3 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| James Sapirstein | Chief Executive Officer |
| James J. Martin | Chief Financial Officer |
| Sam Lee | President and Chief Scientific Officer |
| Roger Kornberg | Chairman of the Board, Chief Scientist and Chairman of Scientific Advisory Board |
Board
| Director | Role |
|---|---|
| Roger Kornberg | Chairman of the Board, Chief Scientist and Chairman of Scientific Advisory Board |
| Steve Rubin | Vice Chairman |
| Carol Brosgart | Director |
| Fred Hassan | Director |
| Phillip Frost | Director |
| Richard C. Pfenniger | Director |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 16, 2026 | +3.0% |
| Q2 2026 | Aug 13, 2026 · Before open | −1.8% |
| Q1 2026 | May 15, 2026 · Before open | −4.8% |
| Q3 2025 | Nov 14, 2025 · Before open | 0.0% |
| Q2 2025 | Aug 14, 2025 · Before open | 0.0% |
| Q1 2025 | May 15, 2025 · Before open | −1.4% |
| Q4 2024 | Mar 26, 2025 · Before open | +1.4% |
| Q3 2024 | Nov 13, 2024 · Before open | +0.6% |
| Q2 2024 | Aug 14, 2024 · Before open | −10.5% |
| Q1 2024 | May 13, 2024 · Before open | 0.0% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q4 2023 | Mar 28, 2024 · Before open | −6.7% |
| Q3 2023 | Nov 13, 2023 · Before open | −1.1% |
| Q2 2023 | Aug 14, 2023 · Before open | +4.2% |
| Q1 2023 | May 15, 2023 · Before open | −5.3% |
| Q4 2022 | Mar 29, 2023 · Before open | +1.7% |
| Q3 2022 | Nov 14, 2022 · Before open | −1.0% |
| Q2 2022 | Aug 15, 2022 · Before open | +4.3% |
| Q1 2022 | May 11, 2022 · Before open | −5.0% |
| Q4 2021 | Mar 23, 2022 · After close | +1.7% |
| Quarter to Sep 30, 2021 | Nov 15, 2021 · Before open | 0.0% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| 2026 International Society For Antiviral Research (ICAR 2026) | Conference | 17 slides | Apr 30, 2026 |
| Investor Presentation (April 2026) | Investor deck | 29 slides | April 2026 |
| 2025 International Calicivirus Conference | Conference | 25 slides | Sep 11, 2025 |
| 2025 Military Health System Research Symposium | Conference | 21 slides | Aug 5, 2025 |
| Life Science Innovation Northwest 2025 | Conference | 12 slides | April 2025 |
| Investor Presentation (January 2025) | Investor deck | 27 slides | Jan 13, 2025 |
| Investor Presentation (January 2024) | Investor deck | 22 slides | Jan 8, 2024 |
| Investor Presentation (December 2023) | Investor deck | 31 slides | Dec 4, 2023 |
| World Vaccine Congress West Coast 2023 | Conference | 18 slides | Nov 29, 2023 |
| 7th ISIRV-AVG Conference 2023 | Conference | 18 slides | May 4, 2023 |
All 29 decks
Financings
| Raise | Date |
|---|---|
| Private placement of common stock Closed: US$5M raised · US$0.9134 a share Buyers: OPKO (5,474,053 shares of common stock for $5.0 million) | Aug 3, 2026 |
| Private placement of units of common stock and unregistered warrants Closed: US$1.03M raised · US$1.39 a unit · Warrants at US$1.24 for 27 months Buyers: Phillip Frost, M.D.; Fred Hassan; Richard Pfenniger; James Martin Insiders: All four investors are insiders: directors Phillip Frost, Fred Hassan and Richard Pfenniger, and co-CEO and CFO James Martin Use of proceeds: Support clinical development programs, working capital and general corporate purposes | Oct 30, 2025 |
| Registered direct offering of shares of common stock with unregistered warrants Closed: US$4.7M raised · US$1.7 a share · Warrants at US$1.5 for 24 months · H.C. Wainwright & Co. Dealers: H.C. Wainwright & Co. (lead) Use of proceeds: Working capital and general corporate purposes | Sep 15, 2025 |
Open Financings · Read by 6ix AI from the company's releases
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 5.43M | 2.01M | 6.56M | 0 | 0 | 0 |
| Cost of revenue | 5.05M | 12.5M | 15.2M | 12.4M | 8.79M | 6.03M | 4.00M | 50.0K | 101.0K | 201.0K |
| Gross profit | -5.05M | -12.5M | -15.2M | -12.4M | -8.79M | -4.02M | 2.56M | -50.0K | -101.0K | -201.0K |
| Research and development | 5.05M | 12.5M | 15.2M | 12.4M | 8.79M | 6.03M | 4.00M | 4.67M | 5.82M | 101.7M |
| Selling, general and administrative | 3.96M | 5.34M | 5.99M | 5.75M | 5.43M | 5.57M | 4.86M | 4.35M | 2.44M | 4.14M |
| Operating income | -9.02M | -17.9M | -18.6M | -38.8M | -14.2M | -9.59M | -48.4M | -62.9M | -8.26M | -105.8M |
| Depreciation and amortization | 72.0K | 126.0K | 189.0K | 185.0K | 190.0K | 157.0K | 98.0K | 50.0K | 101.0K | 201.0K |
| EBITDA | -8.95M | -17.8M | -18.4M | -38.6M | -14.0M | -9.43M | -48.3M | -62.9M | -8.16M | -105.6M |
| Interest expense | -134.0K | -537.0K | -640.0K | 2.00K | 4.00K | 8.00K | 19.0K | 58.0K | 0 | 0 |
| Income before tax | -8.83M | -18.6M | -18.0M | -38.8M | -14.2M | -9.65M | -48.2M | -62.6M | -7.49M | -104.3M |
| Income tax | -17.5M | -1 | 8.00K | 4.00K | 8.00K | 19.0K | -13.6M | -6.88M | -29.4M | |
| Net income | -8.83M | -17.5M | -18.0M | -38.8M | -14.2M | -9.65M | -48.2M | -49.0M | -613.0K | -74.9M |
| Earnings per share, basic | -0.78 | -1.72 | -1.87 | -4.77 | -0.16 | -0.17 | -1.51 | -1.75 | -0.03 | -3.18 |
| Earnings per share, diluted | -0.78 | -1.72 | -1.87 | -4.77 | -0.16 | -0.17 | -1.51 | -1.75 | -0.03 | -3.30 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 7.03M | 9.86M | 26.4M | 37.1M | 58.7M | 33.0M | 7.42M | 2.72M | 748.0K | 3.60M |
| Short-term investments | 29.0K | |||||||||
| Receivables | 706.0K | 1.22M | 890.0K | 716.0K | 0 | 556.0K | 644.0K | 1.00K | 21.0K | |
| Inventory | 75.0K | 50.0K | 50.0K | 29.0K | ||||||
| Current assets | 8.13M | 11.6M | 29.1M | 40.2M | 59.3M | 34.0M | 8.28M | 2.94M | 2.18M | 5.47M |
| Property, plant and equipment | 93.0K | 153.0K | 271.0K | 342.0K | 453.0K | 591.0K | 431.0K | 384.0K | 119.0K | 280.0K |
| Goodwill | 0 | 19.1M | 19.1M | 19.1M | 65.2M | 65.2M | 65.2M | |||
| Total assets | 9.71M | 13.5M | 31.3M | 40.8M | 79.4M | 54.2M | 28.5M | 68.6M | 121.4M | 124.9M |
| Accounts payable | 890.0K | 1.54M | 1.22M | 614.0K | 578.0K | 657.0K | 1.51M | 616.0K | 494.0K | 563.0K |
| Current liabilities | 2.21M | 2.43M | 3.26M | 1.22M | 1.54M | 1.36M | 2.29M | 1.56M | 1.44M | 2.04M |
| Long-term debt | 1.01M | |||||||||
| Total debt | 1.50M | 1.81M | 1.85M | 297.0K | 534.0K | 596.0K | 817.0K | 331.0K | 1.01M | |
| Total liabilities | 3.38M | 3.93M | 4.88M | 1.27M | 1.84M | 1.74M | 2.82M | 1.67M | 16.0M | 22.6M |
| Shareholders' equity | 6.33M | 9.52M | 26.4M | 39.6M | 77.5M | 52.5M | 25.7M | 66.9M | 105.4M | 102.3M |
| Shares outstanding | 13.8M | 10.2M | 10.2M | 8.14M | 8.14M | 70.4M | 35.1M | 29.9M | 24.3M | 23.8M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -8.19M | -16.5M | -14.7M | -21.4M | -12.7M | -9.83M | -1.56M | -8.29M | -6.90M | -14.7M |
| Capital spending | -12.0K | -8.00K | -118.0K | -74.0K | -52.0K | -240.0K | -145.0K | -28.0K | -40.0K | -51.0K |
| Free cash flow | -8.20M | -16.5M | -14.8M | -21.5M | -12.8M | -10.1M | -1.71M | -8.32M | -6.94M | -14.7M |
| Cash from investing | -12.0K | -8.00K | -118.0K | -74.0K | -52.0K | -240.0K | -145.0K | 1.37M | -40.0K | 3.00K |
| Cash from financing | 5.37M | 0 | 3.99M | -27.0K | 38.5M | 35.7M | 6.42M | 8.89M | 4.08M | 9.02M |
| Share buybacks | 35.8M | 6.64M | 7.91M | 711.0K | 9.02M | |||||
| Change in cash | -2.83M | -16.5M | -10.8M | -21.5M | 25.7M | 25.6M | 4.72M | 1.98M | -2.86M | -5.64M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 10-Q · Quarterly report | Nov 16, 2026 | Quarterly report | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Nov 6, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Sep 9, 2026 | Current report | SEC |
| 3 · Initial statement of ownership | Aug 21, 2026 | Insider trade | SEC |
| 8-K · Current report | Aug 18, 2026 | Management or board change | SEC |
| 8-K · Current report | Aug 17, 2026 | Current report | SEC |
| 10-Q · Quarterly report | Aug 13, 2026 | Quarterly report | SEC |
| SCHEDULE 13D · Big-stake notice | Aug 7, 2026 | Big-stake notice | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Aug 7, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Aug 6, 2026 | Insider trade | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 4 · Change in ownership | Aug 5, 2026 | Insider trade | SEC |
| 8-K · Current report | Aug 3, 2026 | Material contract | SEC |
| 8-K · Current report | Jul 17, 2026 | Meeting outcome | SEC |
| 8-K · Current report | Jun 9, 2026 | Management or board change | SEC |
| 4 · Change in ownership | Jun 3, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jun 3, 2026 | Insider trade | SEC |
| 8-K · Current report | Jun 3, 2026 | Current report | SEC |
| DEFA14A · Additional proxy material | May 27, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | May 27, 2026 | Meeting notice | SEC |
| 8-K · Current report | May 26, 2026 | Current report | SEC |
| 10-Q · Quarterly report | May 15, 2026 | Quarterly report | SEC |
| EFFECT · Notice that a registration is effective | May 4, 2026 | Other filings | SEC |
| 8-K · Current report | Apr 30, 2026 | Current report | SEC |
| CORRESP · Letter to the SEC | Apr 29, 2026 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Apr 28, 2026 | Other filings | SEC |
| S-3 · Registration statement | Apr 23, 2026 | Offer document | SEC |
| 8-K · Current report | Apr 2, 2026 | Current report | SEC |
| 10-K · Annual report | Mar 31, 2026 | Annual report | SEC |
| 8-K · Current report | Mar 31, 2026 | Results | SEC |
| 8-K · Current report | Mar 13, 2026 | Management or board change | SEC |
| 8-K · Current report | Mar 9, 2026 | Current report | SEC |
| 4 · Change in ownership | Feb 25, 2026 | Insider trade | SEC |
| 8-K · Current report | Feb 19, 2026 | Current report | SEC |
| 4 · Change in ownership | Feb 9, 2026 | Insider trade | SEC |
| 8-K · Current report | Jan 15, 2026 | Management or board change | SEC |
| 4 · Change in ownership | Jan 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Dec 31, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 29, 2025 | Insider trade | SEC |
| 8-K · Current report | Dec 18, 2025 | Current report | SEC |
| 8-K · Current report | Dec 1, 2025 | Current report | SEC |
| 4 · Change in ownership | Nov 28, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 25, 2025 | Insider trade | SEC |
| 8-K · Current report | Nov 14, 2025 | Results | SEC |
| 10-Q · Quarterly report | Nov 14, 2025 | Quarterly report | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Oct 30, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Oct 30, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 30, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 30, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 30, 2025 | Insider trade | SEC |
| 8-K · Current report | Oct 30, 2025 | Material contract | SEC |
| 8-K · Current report | Oct 27, 2025 | Current report | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Oct 2, 2025 | Big-stake notice | SEC |
| 424B3 · Prospectus | Sep 29, 2025 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Sep 26, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Sep 25, 2025 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Sep 24, 2025 | Other filings | SEC |
| S-1 · Registration statement | Sep 19, 2025 | Offer document | SEC |
| 8-K · Current report | Sep 15, 2025 | Material contract | SEC |
| 424B5 · Prospectus | Sep 15, 2025 | Offer document | SEC |
| 8-K · Current report | Sep 12, 2025 | Current report | SEC |
| 8-K · Current report | Sep 12, 2025 | Current report | SEC |
| 424B3 · Prospectus | Sep 12, 2025 | Offer document | SEC |
| UPLOAD · Letter from the SEC | Aug 28, 2025 | Other filings | SEC |
| 10-Q · Quarterly report | Aug 14, 2025 | Quarterly report | SEC |
| 8-K · Current report | Aug 14, 2025 | Results | SEC |
| CORRESP · Letter to the SEC | Aug 13, 2025 | Other filings | SEC |
| 8-K · Current report | Aug 5, 2025 | Current report | SEC |
| UPLOAD · Letter from the SEC | Jul 30, 2025 | Other filings | SEC |
| 8-K · Current report | Jul 10, 2025 | Current report | SEC |
| 8-K · Current report | Jul 1, 2025 | Meeting outcome | SEC |
| 8-K · Current report | Jun 18, 2025 | Current report | SEC |
| 8-K · Current report | Jun 5, 2025 | Current report | SEC |
| 8-K · Current report | May 29, 2025 | Current report | SEC |
| 8-K · Current report | May 15, 2025 | Results | SEC |
| 10-Q · Quarterly report | May 15, 2025 | Quarterly report | SEC |
| DEFA14A · Additional proxy material | May 5, 2025 | Meeting notice | SEC |
| DEF 14A · Proxy statement | May 5, 2025 | Meeting notice | SEC |
| PRE 14A · Preliminary proxy statement | Apr 25, 2025 | Meeting notice | SEC |
| 8-K · Current report | Apr 24, 2025 | Current report | SEC |
| 8-K · Current report | Apr 23, 2025 | Current report | SEC |
| 8-K · Current report | Apr 8, 2025 | Management or board change | SEC |
| 8-K · Current report | Apr 1, 2025 | Current report | SEC |
| 10-K · Annual report | Mar 31, 2025 | Annual report | SEC |
| 8-K · Current report | Mar 31, 2025 | Results | SEC |
| 8-K · Current report | Jan 13, 2025 | Current report | SEC |
| 8-K · Current report | Jan 8, 2025 | Current report | SEC |
| 8-K · Current report | Dec 31, 2024 | Current report | SEC |
| 8-K · Current report | Nov 13, 2024 | Results | SEC |
| 10-Q · Quarterly report | Nov 13, 2024 | Quarterly report | SEC |
| 8-K · Current report | Oct 31, 2024 | Current report | SEC |
| 4 · Change in ownership | Oct 11, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Oct 11, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Oct 11, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Oct 11, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Oct 11, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Oct 11, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Oct 11, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Oct 11, 2024 | Insider trade | SEC |
| 8-K · Current report | Oct 10, 2024 | Management or board change | SEC |
| 8-K · Current report | Aug 20, 2024 | Current report | SEC |
| 8-K · Current report | Aug 14, 2024 | Results | SEC |
| 10-Q · Quarterly report | Aug 14, 2024 | Quarterly report | SEC |
| 8-K · Current report | Jul 18, 2024 | Current report | SEC |
| 8-K · Current report | Jun 28, 2024 | Meeting outcome | SEC |
| 8-K · Current report | Jun 20, 2024 | Current report | SEC |
| 8-K · Current report | May 13, 2024 | Results | SEC |
| 10-Q · Quarterly report | May 13, 2024 | Quarterly report | SEC |
| DEF 14A · Proxy statement | May 7, 2024 | Meeting notice | SEC |
| 8-K · Current report | May 1, 2024 | Current report | SEC |
| PRE 14A · Preliminary proxy statement | Apr 26, 2024 | Meeting notice | SEC |
| 10-K/A · Annual report, amended | Apr 17, 2024 | Annual report | SEC |
| 10-K · Annual report | Mar 28, 2024 | Annual report | SEC |
| 8-K · Current report | Mar 28, 2024 | Results | SEC |
| 8-K · Current report | Mar 19, 2024 | Current report | SEC |
| 8-K · Current report | Mar 1, 2024 | Current report | SEC |
| 8-K · Current report | Jan 8, 2024 | Current report | SEC |
| 8-K · Current report | Jan 4, 2024 | Current report | SEC |
| SC 13G/A · Big-stake notice, amended | Jan 2, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Dec 21, 2023 | Current report | SEC |
| 8-K · Current report | Dec 6, 2023 | Current report | SEC |
| 8-K · Current report | Dec 4, 2023 | Current report | SEC |
| 8-K · Current report | Nov 29, 2023 | Current report | SEC |
| 8-K · Current report | Nov 13, 2023 | Results | SEC |
| 10-Q · Quarterly report | Nov 13, 2023 | Quarterly report | SEC |
| 8-K · Current report | Oct 31, 2023 | Current report | SEC |
| 8-K · Current report | Aug 16, 2023 | Results | SEC |
| 10-Q · Quarterly report | Aug 14, 2023 | Quarterly report | SEC |
| 4 · Change in ownership | Jul 20, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jul 20, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jul 20, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jul 20, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jul 20, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jul 20, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jul 20, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jul 20, 2023 | Insider trade | SEC |
| 8-K · Current report | Jun 15, 2023 | Current report | SEC |
| 424B5 · Prospectus | Jun 15, 2023 | Offer document | SEC |
| 8-K · Current report | Jun 12, 2023 | Meeting outcome | SEC |
| EFFECT · Notice that a registration is effective | May 30, 2023 | Other filings | SEC |
| CORRESP · Letter to the SEC | May 24, 2023 | Other filings | SEC |
| S-3/A · Registration statement, amended | May 24, 2023 | Offer document | SEC |
| UPLOAD · Letter from the SEC | May 19, 2023 | Other filings | SEC |
| 10-Q · Quarterly report | May 15, 2023 | Quarterly report | SEC |
| 8-K · Current report | May 15, 2023 | Results | SEC |
| S-3 · Registration statement | May 12, 2023 | Offer document | SEC |
| DEF 14A · Proxy statement | Apr 28, 2023 | Meeting notice | SEC |
| 3 · Initial statement of ownership | Apr 27, 2023 | Insider trade | SEC |
| 8-K · Current report | Apr 24, 2023 | Management or board change | SEC |
| SC 13D/A · Big-stake notice, amended | Apr 14, 2023 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Apr 12, 2023 | Big-stake notice | SEC |
| 8-K · Current report | Apr 10, 2023 | Material contract | SEC |
| 4 · Change in ownership | Apr 6, 2023 | Insider trade | SEC |
| 8-K · Current report | Apr 4, 2023 | Current report | SEC |
| 10-K · Annual report | Mar 29, 2023 | Annual report | SEC |
| 8-K · Current report | Mar 15, 2023 | Current report | SEC |
| SC 13G/A · Big-stake notice, amended | Jan 10, 2023 | Big-stake notice | SEC |
| 8-K · Current report | Jan 9, 2023 | Current report | SEC |
| 10-Q · Quarterly report | Nov 14, 2022 | Quarterly report | SEC |
| 8-K · Current report | Oct 26, 2022 | Current report | SEC |
| 8-K · Current report | Oct 3, 2022 | Current report | SEC |
| 8-K · Current report | Sep 12, 2022 | Current report | SEC |
| 10-Q · Quarterly report | Aug 15, 2022 | Quarterly report | SEC |
| 8-K · Current report | Aug 15, 2022 | Results | SEC |
| 4 · Change in ownership | Aug 3, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Aug 3, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Aug 3, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Aug 3, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Aug 3, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Aug 3, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Aug 3, 2022 | Insider trade | SEC |
| 8-K · Current report | Jul 29, 2022 | Management or board change | SEC |
| 8-K · Current report | May 20, 2022 | Meeting outcome | SEC |
| 8-K · Current report | May 19, 2022 | Current report | SEC |
| 10-Q · Quarterly report | May 11, 2022 | Quarterly report | SEC |
| 8-K · Current report | May 11, 2022 | Results | SEC |
| DEF 14A · Proxy statement | Apr 11, 2022 | Meeting notice | SEC |
| PRE 14A · Preliminary proxy statement | Apr 1, 2022 | Meeting notice | SEC |
| 10-K · Annual report | Mar 23, 2022 | Annual report | SEC |
| 8-K · Current report | Mar 23, 2022 | Results | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 10, 2022 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Jan 3, 2022 | Big-stake notice | SEC |
| 8-K · Current report | Dec 22, 2021 | Current report | SEC |
| 8-K · Current report | Nov 19, 2021 | Current report | SEC |
| 10-Q · Quarterly report | Nov 15, 2021 | Quarterly report | SEC |
| 8-K · Current report | Nov 15, 2021 | Results | SEC |
| 8-K · Current report | Sep 14, 2021 | Current report | SEC |
| 4 · Change in ownership | Aug 23, 2021 | Insider trade | SEC |
| 10-Q · Quarterly report | Aug 16, 2021 | Quarterly report | SEC |
| 8-K · Current report | Jul 20, 2021 | Management or board change | SEC |
| 4 · Change in ownership | Jul 20, 2021 | Insider trade | SEC |
| 4 · Change in ownership | Jul 20, 2021 | Insider trade | SEC |
| 4 · Change in ownership | Jul 20, 2021 | Insider trade | SEC |
This page holds 200 of 674 filings. Open Filings
Cap table
Built by 6ix from Cocrystal Pharma, Inc.’s releases · as of Nov 16, 2026
- Common shares
- 19,264,893
- Fully diluted
- 19,264,893
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 19,264,893 | Nov 16, 2026 |
Warrants and options
| Lot |
|---|
| Warrants · US$1.24 · expire about Jan 2028 |
| Warrants · US$1.50 · expire about Sep 2027 |
Share count over time
| Count | Shares |
|---|---|
| Nov 16, 2026 | 19,264,893 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Steve Rubin Other companies: Entera Bio Ltd. (Director · Since at least Feb 1, 2026); Red Violet, Inc. (Director · Since at least Mar 26, 2018); Niagen Bioscience, Inc. (Director · Since at least Mar 27, 2017); OPKO Health, Inc. (Executive VP-Administration, Director · Since at least Feb 9, 2007); VBI Vaccines Inc. (Director · Dec 31, 2016 – Jun 14, 2018 · Past); Fluent, Inc. (Director · Jan 11, 2010 – Apr 13, 2017 · Past); PROLOR Biotech Inc (Director · Jul 23, 2009 – Aug 29, 2013 · Past); Castle Brands Inc (Director · Jan 21, 2009 – Oct 8, 2019 · Past); Non-Invasive Monitoring Systems, Inc. (Director · Oct 30, 2008 – Feb 28, 2012 · Past); BioCardia, Inc. (Interim CEO and Interim CFO, Director · Sep 19, 2008 – Aug 11, 2016 · Past); Asensus Surgical Inc (Director · Sep 4, 2007 – Apr 23, 2013 · Past); Dreams Inc (Director · Jun 25, 2007 – Jun 19, 2009 · Past) | Director · Since at least Mar 17, 2014 |
| James Sapirstein Other companies: INmune Bio Inc. (Director · Since at least Sep 8, 2026); ZyVersa Therapeutics, Inc. (Director · Since at least Jan 5, 2023); Onconetix, Inc. (Director · Feb 23, 2022 – Sep 26, 2024 · Past); Blue Water Acquisition Corp (Director · Dec 15, 2020 – Dec 15, 2020 · Past); Marizyme, Inc. (Interim CEO, Director · Sep 10, 2020 – Mar 5, 2021 · Past); GridAI Technologies Corp. (Chairman and CEO, Director · Oct 8, 2019 – Jul 2, 2024 · Past); Lunai Bioworks Inc. (Director · Mar 6, 2018 – Jun 25, 2024 · Past); Hepion Pharmaceuticals, Inc. (Chief Executive Officer, Director · Jan 3, 2018 – Jan 3, 2018 · Past); RespireRx Pharmaceuticals Inc (Director · Dec 9, 2017 – Dec 9, 2017 · Past) | Chief Executive Officer · Since at least Jun 3, 2026 |
| Richard C Pfenniger Jr Other companies: Fluent, Inc. (Director · Since at least Oct 6, 2022); GeneDx Holdings Corp. (Director · Since at least Apr 29, 2022); OPKO Health, Inc. (Director · Since at least Jan 24, 2008); BioCardia, Inc. (Director · Oct 24, 2016 – Dec 31, 2020 · Past); Wright Investors' Service Holdings, Inc. (Director · Mar 31, 2015 – Oct 22, 2018 · Past); Asensus Surgical Inc (Director · Aug 24, 2007 – Aug 22, 2024 · Past); Continucare Corp (CEO and President, Director · Mar 24, 2006 – Oct 4, 2011 · Past); Ivax Corp (Director · Jan 26, 2006 – Jan 26, 2006 · Past); GP Strategies Corporation (Director · Feb 2, 2005 – Oct 14, 2021 · Past) | Director · Since at least May 27, 2021 |
| Fred Hassan Other companies: Recursion Pharmaceuticals, Inc. (Director · Since Oct 31, 2026); EyePoint, Inc. (Director · Since at least Sep 3, 2024); BridgeBio Pharma, Inc. (Director · Since at least Aug 17, 2021); Precigen, Inc. (Director · Since at least Jun 30, 2016); Prometheus Biosciences Inc (Director · May 14, 2021 – Jun 16, 2023 · Past); Time Warner Inc (Director · Jun 1, 2016 – Jun 14, 2018 · Past); Amgen Inc. (Director · Jul 28, 2015 – May 5, 2020 · Past) | Director · Since at least Apr 20, 2023 |
| Jane Hsiao Other companies: OPKO Health, Inc. (Vice Chairman and Chief Technical Officer · Since at least Feb 9, 2007); Sorrento Therapeutics, Inc. (Director · Jan 25, 2010 – Feb 6, 2012 · Past); PROLOR Biotech Inc (Director · Jul 23, 2009 – Aug 29, 2013 · Past); Non-Invasive Monitoring Systems, Inc. (Interim CEO, Director · Oct 30, 2008 – Dec 21, 2018 · Past); Asensus Surgical Inc (Director · Aug 24, 2007 – Jun 30, 2021 · Past); Protalix BioTherapeutics, Inc. (de) (Director · Dec 31, 2006 – Jan 31, 2007 · Past); Ivax Corp (Vice Chairman and CTO, Director · Jan 26, 2006 – Jan 26, 2006 · Past) | Director · Mar 17, 2014 – Sep 21, 2018 · Past |
| Carol Brosgart Other companies: Galmed Pharmaceuticals Ltd. (Director · Since at least Mar 18, 2026); Mirum Pharmaceuticals, Inc. (Director · Jun 4, 2021 – Jun 2, 2022 · Past); Lunai Bioworks Inc. (Director · Dec 27, 2019 – Jun 25, 2024 · Past); Tobira Therapeutics Inc (Director · Jul 9, 2015 – Nov 1, 2016 · Past) | Director · Since at least Aug 12, 2026 |
| Fred Hassan Other companies: Recursion Pharmaceuticals, Inc. (Chair of the Board · Since at least Nov 2, 2026); EyePoint, Inc. (Board Member · Since at least Nov 7, 2024) | Director · Since at least Oct 30, 2025 |
| James J. Martin Other companies: PetVivo Holdings Inc (Director · Mar 12, 2021 – May 24, 2021 · Past); SAB Biotherapeutics, Inc. (Director · Jan 11, 2021 – Jan 11, 2021 · Past) | Chief Financial Officer · Since at least Feb 23, 2017 |
| Roger Kornberg Other companies: Xenetic Biosciences, Inc. (Non-Executive Director · Since at least Nov 1, 2016); Big Digital Energy, Inc. (Director · Jun 11, 2013 – Jun 11, 2013 · Past) | Chairman of the Board, Chief Scientist and Chairman of Scientific Advisory Board · Since at least Mar 17, 2014 |
| Walt Addison Linscott Other companies: Indaptus Therapeutics, Inc. (Chief Operating Officer · Since at least Jul 23, 2021); Intec Pharma Ltd (Chief Business Officer · Jan 1, 2019 – Sep 16, 2020 · Past) | GENERAL COUNSEL AND SECRETARY · Jul 21, 2015 – Jul 21, 2015 · Past |
All 19 people
| Person | Seat |
|---|---|
| Anthony J Japour Other companies: OPKO Health, Inc. (Director · Jan 6, 2020 – Mar 12, 2020 · Past) | Director · Since at least Apr 4, 2019 |
| Douglas L Mayers Other companies: Idenix Pharmaceuticals Inc (EVP and Chief Medical Officer · Mar 29, 2007 – Aug 5, 2014 · Past) | CHIEF MEDICAL OFFICER · Oct 1, 2015 – Oct 1, 2015 · Past |
| Phillip Frost Other companies: OPKO Health, Inc. (CEO & Chairman, Director · Since at least May 10, 2022) | Director · Since at least Jul 25, 2022 |
| Raymond F Schinazi Other companies: Precision BioSciences, Inc. (Director · Mar 27, 2019 – May 10, 2022 · Past) | Director · Nov 25, 2014 – Sep 21, 2018 · Past |
| Richard C. Pfenniger Other companies: OPKO Health, Inc. (Director · Since at least Nov 5, 2026) | Director · Since at least Oct 30, 2025 |
| Steve Rubin Other companies: OPKO Health, Inc. (Executive Vice President, Administration and Director · Since at least Feb 4, 2026) | Vice Chairman · Since at least Nov 4, 2026 |
| David S Block | Director · Nov 25, 2014 – Sep 21, 2018 · Past |
| Sam Lee | President and Co-CEO · Since at least Oct 9, 2024 |
| Sam Lee | President and Chief Scientific Officer · Since at least Sep 9, 2026 |
Log in to ask 6ix AI your own questions about Cocrystal Pharma, Inc.